Abstract
Deregulation of c-Myc (referred to as MYC] contributes to the development of the most human tumors [1–3]. In addition to MYC, the Myc gene family contains three related genes, N-Myc, L-Myc, and S-Myc, which are also implicated in the genesis of specific human tumors (for review, see ref [4]). MYC is a nuclear transcription factor, which is first identified as the cellular homologue of the cancer-causing gene in the avian myelocytomatosis retrovirus [5]. MYC functions in a heterodimeric complex with MAX to bind E-Box motifs in DNA, and transcriptionally regulates hundreds to thousands of target genes. The most recent estimates suggest that MYC could regulate as many as 15% of genes in genomes from flies to human [6]. A compilation of MYC-regulated genes and studies on MYC alterations in human cancers is available online at www.myccancergene.org [6]. This database emphasizes both the critical role of MYC in human cancers and the significance of MYC target genes in driving its oncogenic activity. The target genes are involved in diverse programs including cell cycle, cell growth, protein synthesis, cell adhesion and cytoskeleton, metabolism, apoptosis, angiogenesis, DNA repair, and microRNA [6–8]. The diversity of MYC target genes is illustrated in Fig. 24.1. Numerous excellent and comprehensive reviews have been written about MYC [9–12]. Therefore, in this chapter, we will focus mainly on the role of MYC in cancer with the emphasis on the most recent findings.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nesbit CE, Tersak JM, Prochownik EV (1999) MYC oncogenes and human neoplastic disease. Oncogene 18: 3004–3016
Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19:1–11
Pelengaris S, Khan M, Evan G (2002) c-MYC: more than just a matter of life and death. Nat Rev Cancer 2:764–776
Adhikary S, Eilers M (2005) Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6: 635–645
Bishop JM (1982) Retroviruses and cancer genes. In: George Kline SW (ed) Advances in cancer research, 37. Academic Press Inc., New York, pp 1–32
Dang CV, O’Donnell KA, Zeller KI et al (2006) The c-Myc target gene network. Semin Cancer Biol 16:253–264
Oster SK, Ho CS, Soucie EL et al (2002) The MYC oncogene: marvelously complex. Adv Cancer Res 84:81–154
Alitalo K, Schwab M (1986) Oncogene amplification in tumor cells. Adv Cancer Res 47:235–281
Meyer N, Penn LZ (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8:976–990
Eilers M, Eisenman RN (2008) Myc’s broad reach. Genes Dev 22:2755–2766
Secombe J, Pierce SB, Eisenman RN (2004) Myc: a weapon of mass destruction. Cell 117:153–156
Eisenman RN (2001) Deconstructing myc. Genes Dev 15: 2023–2030
Lau LF, Nathans D (1987) Expression of a set of growth-related immediate early genes in BALB/c 3 T3 cells: coordinate regulation with c-fos or c-myc. Proc Natl Acad Sci U S A 84:1182–1186
Lanahan A, Williams JB, Sanders LK et al (1992) Growth factor induced delayed early response genes. Mol Cell Biol 12:3919–3929
Kim SY, Herbst A, Tworkowski KA et al (2003) Skp2 regulates Myc protein stability and activity. Mol Cell 11: 1177–1188
Salghetti SE, Kim SY, Tansey WP (1999) Destruction of Myc by ubiquitinmediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 18: 717–726
Lutterbach B, Hann SR (1999) c-Myc transactivation domain-associated kinases: questionable role for map kinases in c-Myc phosphorylation. J Cell Biochem 72: 483–491
Lutterbach B, Hann SR (1994) Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 14:5510–5522
Sears R, Leone G, DeGregori J et al (1999) Ras enhances Myc protein stability. Mol Cell 3:169–179
Yeh E, Cunningham M, Arnold H et al (2004) A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 6:308–318
Sakamuro D, Prendergast GC (1999) New Myc-interacting proteins: a second Myc network emerges. Oncogene 18: 2942–2954
Sakamuro D, Elliott KJ, Wechsler-Reya R et al (1996) BIN1 is a Novel MYC-interacting protein with features of a tumour suppressor. Nat Genet 14:69–77
Eilers M, Picard D, Yamamoto KR et al (1989) Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature 340:66–68
Eberhardy SR, Farnham PJ (2001) c-Myc mediates activation of the cad promoter via a post-RNApolymerase II recruitment mechanism. J Biol Chem 276:48562–48571
Zeller KI, Haggerty TJ, Barrett JF et al (2001) Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation. J Biol Chem 76: 48285–48291
Mao DY, Watson JD, Yan PS et al (2003) Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol 13:882–886
Haggerty TJ, Zeller KI, Osthus RC et al (2003) A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc Natl Acad Sci U S A 100:5313–5318
Coller HA, Grandori C, Tamayo P et al (2000) Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 97:3260–3265
Guo QM, Malek RL, Kim S et al (2000) Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 60:5922–5928
Schuldiner O, Benvenisty N (2001) A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors. Oncogene 20:4984–4994
Marinkovic D, Marinkovic T, Kokai E et al (2004) Identification of novel Myc target genes with a potential role in lymphomagenesis. Nucleic Acids Res 32:5368–5378
Lawlor ER, Soucek L, Brown-Swigart L et al (2006) Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Res 66:4591–4601
O’Connell BC, Cheung AF, Simkevich CP et al (2003) A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 278:12563–12573
Ellwood-Yen K, Graeber TG, Wongvipat J et al (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4:223–238
Lee JS, Chu IS, Mikaelyan A et al (2004) Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36:1306–1311
Wu CH, Sahoo D, Arvanitis C et al (2008) Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. PLoS Genet 4:1–16
Sahoo D, Dill DL, Tibshirani R et al (2007) Extracting binary signals from microarray time-course data. Nucleic Acids Res 35:3705–3712
Liu J, Levens D (2006) Making myc. Curr Top Microbiol Immunol 302:1–32
Rabbitts PH, Watson JV, Lamond A et al (1985) Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J 4:2009–2015
Ramsay G, Evan GI, Bishop JM (1984) The protein encoded by the human proto-oncogene c-myc. Proc Natl Acad Sci U S A 81:7742–7746
Popescu NC, Zimonjic DB (2002) Chromosome-mediated alterations of the MYC gene in human cancer. J Cell Mol Med 6:151–159
Spencer CA, Groudine M (1991) Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res 56:1–48
Sears R, Leone G, DeGregori J et al (1999) Ras enhances Myc protein stability. Mol Cell 3:169–79
He TC, Sparks AB, Rago C et al (1998) Identification of c-MYC as a target of the APC pathway. Science 281:1509–12
Kolligs FT, Bommer G, Goke B (2002) Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 66:131–144
Evan G, Littlewood T (1998) A matter of life and cell death. Science 281:1317–1322
Lowe SW, Cepero E, Evan G (2004) Intrinsic tumour suppression. Nature 432:307–315
Eischen CM, Weber JD, Roussel MF et al (1999) Disruption of the ARF-Mdm2–p53 tumor suppressor pathway in Mycinduced lymphomagenesis. Genes Dev 13:2658–2669
Kamijo T, Weber JD, Zambetti G et al (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 95:8292–8297
Schmitt CA, McCurrach ME, de Stanchina E et al (1999) INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13: 2670–2677
Zindy F, Eischen CM, Randle DH et al (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12:2424–2433
Askew DS, Ashmun RA, Simmons BC et al (1991) Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6:1915–1922
Evan GI, Wyllie AH, Gilbert CS et al (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119–128
Murphy DJ, Junttila MR, Pouyet L et al (2008) Distinct thresholds govern Myc’s biological output in vivo. Cancer Cell 14:447–457
Freie BW, Eisenman RN (2008) Ratcheting Myc. Cancer Cell 14:425–426
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Selected Readings
Selected Readings
1. Eisenman RN. Deconstructing myc. Genes Dev. 2001;15:2023-30 (comprehensive analysis of the problem derives from the apparent gap between Myc’s biological role and what is surmised to be its molecular function)
2. Eilers M, Eisenman RN. Myc’s broad reach. Genes Dev. 2008; 22:2755 (two major aspects of MYC - the nature of the genes and pathways that are targeted by Myc, and the role of MYC in stem cell and cancer biology - are reviewed in this article
3. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8:976-990 (in this article the authors chronicle the major advances in our understanding of MYC biology since the discovery of MYC 25 years ago, and examine the future trends of MYC research)
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Thorgeirsson, S.S., Factor, V.M. (2010). The MYC Network and Cancer. In: Dufour, JF., Clavien, PA. (eds) Signaling Pathways in Liver Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-00150-5_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-00150-5_24
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-00149-9
Online ISBN: 978-3-642-00150-5
eBook Packages: MedicineMedicine (R0)